Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement

Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement

Abstract: Patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) with central nervous system (CNS) involvement (CNS B-ALL) have poor outcomes and were frequently excluded from CD19-targeting chimeric antigen receptor (CAR) T-cell clinical trials. The efficacy and safety...

Full description

Saved in:
Bibliographic Details
Main Authors: Ibrahim N. Muhsen, Gregory W. Roloff, Rawan Faramand, Tamer Othman, Yannis Valtis, Noam E. Kopmar, Simone E. Dekker, Matthew Connor, Santiago Mercadal, Timothy E. O'Connor, Kaitlyn C. Dykes, Mohamed Ahmed, Nikeshan Jeyakumar, Amy Zhang, Katharine Miller, Katherine C. Sutherland, Caitlin Guzowski, Vishal K. Gupta, Navneet Majhail, Minoo Battiwalla, Melhem M. Solh, Shahbaz A. Malik, John Mathews, Caspian H. Oliai, Paul Shaughnessy, Luke Mountjoy, Catherine J. Lee, Aaron C. Logan, Stephanie B. Tsai, Jessica T. Leonard, Marc Schwartz, Joshua P. Sasine, Muthu Kumaran, Noelle Frey, Jae H. Park, Divya Koura, Ryan D. Cassaday, Bijal D. Shah, Ibrahim Aldoss, Lori S. Muffly, LaQuisa C. Hill
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S247395292500271X
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S247395292500271X

Similar Items